Treatment of Crohn’s Disease with Leflunomide as Second-Line Immunosuppression

@article{Holtmann2008TreatmentOC,
  title={Treatment of Crohn’s Disease with Leflunomide as Second-Line Immunosuppression},
  author={Martin H. Holtmann and A. L. Gerts and Arndt Weinman and Peter Robert Galle and Markus Friedrich Neurath},
  journal={Digestive Diseases and Sciences},
  year={2008},
  volume={53},
  pages={1025-1032}
}
The aim of this study was to assess the potential of leflunomide, an immunosuppressant in rheumatoid arthritis, as a second-line immunosuppression treatment of patients with Crohn's disease refractory or intolerant to azathioprine. The study cohort consisted of 24 patients. The primary end point was steroid-free remission, and secondary end points were changes in the Crohn's disease activity index (CDAI) and steroid intake, responsiveness of arthralgias and adverse events. Results were… 

Clinical expression of leflunomide-induced pneumonitis.

The current evidence of LEF-induced pneumonitis (LEIP) will help rheumatologists recognize suspected cases of LEIP and to influence clinical guidelines, and clinical guidelines should be used with caution in patients with ILD.

Efficacy of leflunomide for treatment of immune-mediated polyarthritis in dogs: 14 cases (2006-2008).

Oral administration of leflunomide was a safe and effective alternative to oral administration of corticosteroids for treatment of IMPA in dogs, and a starting dosage of 3 to 4 mg/kg PO once daily for at least 6 weeks is recommended.

A Retrospective Study on the Safety and Efficacy of Leflunomide in Dogs

Results suggest that the starting dosage of leflunomide should be 2 mg/kg/d rather than the currently suggested dosage of 3–4 mg/ kg/d.

Drug Screen Identifies Leflunomide for Treatment of Inflammatory Bowel Diseases Caused by TTC7A Deficiency.

In zebrafish with disruption of ttc7a, leflunomide restores gut motility, reduces intestinal tract narrowing, and increases intestinal cell survival, and this drug might be repurposed for treatment of TTC7A deficiency.

Baicalin attenuates TNBS-induced colitis in rats by modulating the Th17/Treg paradigm

The study showed that baicalin not only significantly attenuated TNBS-induced colitis by reducing the disease activity index as well as macroscopic and microscopic scores, but it also improved the weight loss and shortening of the colon.

4SC‐101, a novel immunosuppressive drug, inhibits IL‐17 and attenuates colitis in two murine models of inflammatory bowel disease†

In vitro, 4 SC‐101 is a potent inhibitor of human DHODH, inhibits lymphocyte proliferation, and uniquely blocks phytohemagglutinin‐stimulated IL‐17 production by lymphocytes, and in vivo, oral administration of 4SC‐101 effectively improved both chronic DSS and acute TNBS colitis in mice.

Total Glycosides of Peony Protects Against Inflammatory Bowel Disease by Regulating IL-23/IL-17 Axis and Th17/Treg Balance.

It is demonstrated that administration of TGP effectively attenuates colonic inflammation of TNBS-induced colitis mice, mainly reflected in significantly improved clinical parameters, reduced inflammatory response and myeloperoxidase (MPO) activity, even stronger systemic immune ability and effective improvement of Th17/Treg immune disorders.

Возможности применения лефлуномида при ревматических заболеваниях

The encouraging results of preliminary studies of the efficacy of leflunomide in Crohn"s disease, Wegener"s granulomatosis, and systemic lupus erythematosus need to be confirmed in large-scale randomized controlled studies.

References

SHOWING 1-10 OF 25 REFERENCES

Leflunomide Treatment of Crohn's Disease Patients Intolerant to Standard Immunomodulator Therapy

It is demonstrated that the pyrimidine analog leflunomide may be effective for treating moderate to severe CD patients intolerant to standard immunomodulator therapy and warrants further investigation in a randomized controlled trial.

A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.

Both leflunomide and methotrexate are efficacious for prolonged treatment of RA and this benefit must be weighed against the potential toxicity of this drug when used without folate supplementation.

Effectiveness and safety profile of leflunomide in rheumatoid arthritis: actual practice compared with clinical trials.

The differences between the two populations confirm the need to conduct post-marketing studies in order to obtain better knowledge on the effectiveness and safety of a new drug.

Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience.

The blood count has been reviewed in all patients treated with azathioprine for inflammatory bowel disease over 27 years in one hospital and leucopenia is the commonest and most important haematological complication.

Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis

Improved efficacy at the 25-mg dose was associated with a higher incidence of AEs, and Randomized, placebocontrolled trials using daily doses of 10 mg and 20 mg are under way in the US and Europe to confirm these positive results.

Long-Term Effectiveness of Azathioprine in IBD Beyond 4 Years: A European Multicenter Study in 1176 Patients

The results support a novel differential algorithm for long-term azathioprine therapy in IBD and may be considered after 3–4 years in CD patients in complete remission without steroid requirement and for UC patients in general, continuation seems beneficial.

Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease.

Azathioprine and 6-mercaptopurine are effective therapy for inducing remission in active Crohn's disease and the odds ratio of response increases after >/= 17 weeks of therapy, suggesting that there is a minimum length of time for a trial of azathiopine or 6-MERcaptopirine therapy.